BridgeBio Pharma胜于或起源于分析师的评级,侧重于库存波动性较高但上上浮潜力较大的遗传疾病。 BridgeBio Pharma surpasses Orgenesis in analyst ratings, focusing on genetic diseases with higher stock volatility but greater upside potential.

分析家认为BridgeBio Pharma比Orgin的投资要好,在11个因素中的9个方面表现优于Orgin。 BridgeBio Pharma is seen as a better investment than Orgenesis by analysts, outperforming on nine of eleven factors. 它侧重于遗传疾病和癌症,在高级试验中使用AG10这样的产品。 It focuses on genetic diseases and cancers, with products like AG10 in advanced trials. 同时,也开始专门研究细胞和基因疗法 Meanwhile, Orgenesis specializes in cell and gene therapies. BridgeBio的股份价格比S&P 500多8%,而Origin为31%。 BridgeBio's share price is 8% more volatile than the S&P 500, compared to Orgenesis at 31%. BridgeBio公司有一个一致的物价目标,即潜在上扬73.49%。 BridgeBio has a consensus price target suggesting a potential 73.49% upside.